Skip to main content

Akoya Biosciences to Host Inaugural Spatial Day on December 15, 2021

Written by Customer Service on . Posted in Public Companies.

The program will highlight the latest breakthroughs and applications in spatial biology and the company’s latest innovations to accelerate breakthroughs in discovery and clinical research.

MARLBOROUGH, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will host an inaugural Spatial Day on December 15, 2021 at 12 p.m. ET. The program will feature Akoya speakers and experts at the forefront of this new field who will discuss how spatial biology is uniquely positioned to address challenges in discovery, translational and clinical research, where the field is headed, and Akoya’s vision for the future.

Akoya is a pioneer in the rapidly emerging field of spatial phenotyping, a transformational new application that is giving unprecedented context to cell-cell interactions within tissue biology. Understanding spatial biomarker signatures within the framework of spatial phenotyping has the potential to unlock an explosion of new applications in medicine and research, such as the ability to segment patient populations based on immune interactions, development of spatial diagnostic assays, drug discovery, and design or identification of personalized therapeutic interventions. Biomarkers that predict response or resistance to drugs, based on understanding specific types and subtypes of immune cells and the ability to map their spatial distribution, are among the most advanced opportunities with spatial phenotyping.

The agenda and speakers are as follows:

  • Welcome & Introduction, Brian McKelligon, CEO, Akoya
  • Revolutionizing Our Understanding of Disease Biology, Kai Kessenbrock, PhD, Principal Investigator, Human Cell Atlas Initiative, University of California, Irvine, CA, and Robert Schreiber, PhD, Professor of Pathology, Washington University, St. Louis, MO
  • Q&A Roundtable, hosted by Niro Ramachandran, PhD, CBO, Akoya
  • Changing the Standard of Care Using Spatial Biomarkers, Carl Barrett, PhD, VP, Translational Medicine, AstraZeneca plc, and Kurt Schalper, MD, PhD, Professor of Pathology and Oncology, Yale University, New Haven, CT
  • Q&A Roundtable, hosted by Pascal Bamford, PhD, SVP, R&D, Akoya
  • The Future Direction of Akoya, Niro Ramachandran, PhD, CBO, Akoya
  • Closing remarks, Brian McKelligon, CEO, Akoya
  • Audience Q&A

To register for the event please visit www.akoyabio.com/spatialday.

About Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. Akoya offers two distinct solutions, the CODEX® and Phenoptics™ platforms, to serve the diverse needs of researchers across discovery, translational and clinical research.

Investor Contact:
Priyam Shah
Akoya Biosciences
investors@akoyabio.com

Media Contact:
Michelle Linn
Bioscribe, Inc.
774-696-3803
michelle@bioscribe.com 

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.